丝氨酸／苏氨酸激酶15和突变型p53蛋白在甲状腺癌中的表达及其意义

目的探讨中心体扩增相关的丝氨酸／苏氨酸激酶（STK）15和突变p53基因（mtp53）在甲状腺癌中的表达及其生物学意义。方法采用免疫组织化学sP法检测5l例甲状腺癌、20例甲状腺瘤和19例甲状腺癌旁正常组织中STKl5和mtp53蛋白的表达，对数据进行统计学分析。结果mtp53表达于细胞核，在甲状腺癌组织中表达率为74．5％（38／51），在甲状腺瘤组织表达率为25．0％（5／20），全部为低表达，在甲状腺癌旁正常组织中mtp53未见表达，mtp53在三种组织中表达差异有统计学意义（χ^2=36．149，P=0．000）；STKl5为胞质和胞核表达，在甲状腺癌组织中表达率为72．5％（37／51），在甲状腺瘤组织中表达率为20．0％（4／20），在癌旁正常甲状腺组织中不表达，STKl5在三种组织中的表达率差异有统计学意义（X^2=6．147，P=0．000）；甲状腺癌组织中mtp53和STKl5表达呈正相关（r=0．802，P=0．000）。结论甲状腺癌的发生与p53突变及STKl5扩增有关。野生型p53基因突变后与中心体扩增有关的STKl5激酶的扩增可能在甲状腺癌发生中扮演重要角色，STKl5有望成为甲状腺癌治疗的靶点。

Expression and biological significance of mutant p53 and STK15 in thyroid carcinoma

Objective To study the expression of mutant p53 （mtp53） and STK15 in thyroid carcinoma and explore their biological significance. Methods Immunohistoehemistry SP method was used to detect the expressions of mtp53 and STK15 in 51 patients with thyroid carcinoma, 20 patients with thyroid adenoma and 19 patients with ngrmal thyroid tissue. The data were analyzed with SPSS 13.0 software. Results The nucleus expression of mtp53 was found in thyroid carcinoma with the positive rate of 74.5 % （38/51） and 25.0 % （5/20） in thyroid adenoma with low expression and mtp53 positive product wasn＇ t found in normal thyroid tissues. The mtp53 protein had significant differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissues （χ^2 = 36.149, P = 0.000）. The positive products of STK15 were found in the cytoplasm and nucleus of thyroid carcinoma and the expression rate was 72.5 % （37/51）. A weak positive expression of STK15 was seen in thyroid adenoma and the positive rate was 20.0 % （4/20）. STK15 protein wasn＇t found in normal thyroid tissues. The STK15 protein had significant differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue （X^2 = 36.147, P = 0.000）. In addition, the expressions of mtp53 and STK15 were positively correlated （r = 0.802, P = 0.000）. Conclusions There are significant associations between mtp53 expression and STK15 expression in thyroid carcinoma. STK15 amplicated after mtp53 mutations might play important roles in the tumorigenesis in the thyroid carcinoma, suggesting it might be a therapeutic target for the treatment of thyroid carcinoma.